Elite Pharmaceuticals (ELTP) AI Stock Analysis

• Market Cap: $653.39M
• Dividend Yield: N/A
• Average Volume (3M): 951.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: 72.67%
• EPS Growth: N/A
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): <0.01
• Shares Outstanding: 1,070,963,100
• 10 Day Avg. Volume: 753,540
• 30 Day Avg. Volume: 951,200
• PEG Ratio: 0.90
• Price to Book (P/B): 8.68
• Price to Sales (P/S): 5.53
• P/FCF Ratio: 94.25
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: 3.78
• Enterprise Value/Gross Profit: 7.18
• Enterprise Value/Ebitda: 17.75
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: $0.50 ▼(-3.85% Downside)

Elite Pharmaceuticals' strong revenue growth and improved operating profits are significant positives, supported by a robust product pipeline and market presence. However, profitability challenges, high P/E ratio, and competitive pressures weigh on the overall score.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and effective product strategies, enhancing Elite's competitive position and long-term growth prospects.

Strong Operating Profit

Improved operating profits reflect efficient cost management and successful product launches, which are crucial for sustaining profitability and reinvestment in growth.

Strengthened Balance Sheet

A stronger balance sheet with increased working capital enhances financial stability and provides flexibility for future investments and strategic initiatives.

Negative Factors

Increased Competition

Rising competition pressures margins and could erode market share, challenging Elite's ability to maintain its growth trajectory and profitability.

Higher Administrative Costs

Rising administrative and compliance costs can strain profitability, requiring careful management to avoid impacting operational efficiency and financial health.

DEA Quota Impact

While increased quotas benefit Elite, they also aid competitors, potentially diluting market share and impacting long-term competitive advantage.

Elite Pharmaceuticals Business Overview & Revenue Model

Company Description

Elite Pharmaceuticals, Inc. (ELTP) is a specialty pharmaceutical company focused on the development and commercialization of innovative drug delivery systems and products. The company operates primarily in the pharmaceutical sector, with a focus on developing oral and injectable dosage forms. Elite Pharmaceuticals specializes in the formulation of generic and proprietary therapeutics, particularly in the areas of pain management, addiction, and other therapeutic categories, leveraging its advanced drug delivery technologies to enhance the bioavailability and efficacy of its products.

How the Company Makes Money

Elite Pharmaceuticals generates revenue through several key streams. Primarily, the company earns money by developing and selling generic pharmaceuticals, which are typically marketed under its own brand or through partnerships with larger pharmaceutical firms. The company also engages in contract manufacturing for other pharmaceutical companies, providing formulation development and production services. Additionally, Elite Pharmaceuticals has entered into licensing agreements for its proprietary drug delivery technologies, allowing it to earn royalties from its partners. These revenue streams are supported by strategic partnerships with other pharmaceutical companies and collaborations that enhance its market reach and product offerings.

Elite Pharmaceuticals Financial Statement Overview

Summary

Elite Pharmaceuticals shows strong revenue growth but struggles with profitability due to net losses and fluctuating margins. The balance sheet is robust with adequate equity and controlled debt levels, but cash flow inconsistencies highlight areas for improvement in operational efficiency.

Income Statement

Elite Pharmaceuticals shows a strong revenue growth trajectory, with significant increases in revenue over the past few years. Despite the growth, the company faced a net loss in the latest period, impacting the net profit margin negatively. However, the gross profit margin remains robust, indicating efficient production. The variability in EBITDA margin over the years suggests operational challenges that need addressing.

Balance Sheet

The balance sheet reveals a healthy equity position with a favorable equity ratio, indicating strong financial resilience. The debt-to-equity ratio is manageable, suggesting moderate leverage, which poses less risk to financial stability. Return on equity has fluctuated significantly, reflecting volatility in profitability.

Cash Flow

Cash flow analysis indicates inconsistent free cash flow performance, with recent positive growth but past periods of negative free cash flow. The operating cash flow to net income ratio suggests that cash generation from operations can improve. The company's ability to convert net income into cash remains a challenge, as evidenced by the free cash flow to net income ratio.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	122.89M	84.04M	56.63M	34.16B	32.26M	25.38M
Gross Profit	64.71M	40.09M	26.36M	16.59B	14.80M	11.87M
EBITDA	26.17M	2.84M	2.52M	6.43M	6.49M	3.63M
Net Income	13.92M	-4.31M	20.11M	4.41B	8.90M	5.09M
Balance Sheet
Total Assets	117.25M	96.39M	83.65M	40.90M	35.15M	26.19M
Cash, Cash Equivalents and Short-Term Investments	26.62M	11.32M	7.11M	7.83M	8.54M	3.19M
Total Debt	3.32M	10.91M	11.74M	3.89M	2.78M	2.38M
Total Liabilities	44.99M	42.87M	26.07M	11.94M	9.93M	10.04M
Stockholders Equity	61.58M	53.52M	57.58M	28.96M	25.22M	16.15M
Cash Flow
Free Cash Flow	21.66M	4.93M	-4.09M	-2.40M	6.01M	2.86M
Operating Cash Flow	22.73M	7.46M	-3.28M	3.34M	6.51M	3.19M
Investing Cash Flow	-1.08M	-2.40M	-809.65K	-5.74M	-498.57K	-262.78K
Financing Cash Flow	-4.58M	-825.74K	3.39M	1.70M	-667.13K	-869.83K

Elite Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTP, the sentiment is Negative. The current price of 0.52 is below the 20-day moving average (MA) of 0.57, below the 50-day MA of 0.60, and below the 200-day MA of 0.56, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 35.08 is Neutral, neither overbought nor oversold. The STOCH value of 29.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELTP.

Elite Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	76 Outperform	$1.25B	12.04	14.84%	―	-0.03%	-27.66%
SIGA	73 Outperform	$582.87M	7.09	39.94%	―	-0.85%	-13.50%
ELTP	70 Outperform	$653.39M	-60.40	25.58%	―	72.67%	―
ORGO	60 Neutral	$624.41M	―	0.30%	―	2.24%	-67.56%
AVDL	57 Neutral	$2.09B	―	-0.32%	―	79.88%	99.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AQST	41 Neutral	$778.38M	―	―	―	-26.32%	-56.54%

Elite Pharmaceuticals Corporate Events

Elite Pharmaceuticals Reports Strong Financial Turnaround

Elite Pharmaceuticals, Inc., a Nevada-based company, specializes in the research, development, licensing, manufacturing, and sales of generic, oral dose pharmaceuticals, focusing on controlled-release products for therapeutic areas such as allergy, bariatric, and Parkinson’s disease.

Elite Pharmaceuticals Reports 92% Revenue Growth in Q2

Elite Pharmaceuticals, Inc. reported significant financial growth for the second quarter of fiscal year 2026, ending September 30, 2025, with consolidated revenues reaching $36.3 million, marking a 92% increase from the same period in the previous fiscal year. This growth was largely driven by the successful launch of lisdexamfetamine products and strong performance of the Elite label product lines, resulting in an income from operations of $8.2 million, a 136% increase from the prior year.

The most recent analyst rating on (ELTP) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Elite Pharmaceuticals stock, see the ELTP Stock Forecast page.

Elite Pharmaceuticals Gains FDA Approval for Generic Drug

On November 12, 2025, Elite Pharmaceuticals announced it received FDA approval for a generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), used to treat Parkinson’s disease symptoms. This approval allows Elite to market the product under its Elite Laboratories label, potentially impacting the company’s market presence in the niche generic pharmaceutical sector, with the branded product and its equivalents having U.S. sales of $10 million for the twelve months ending September 2025.

The most recent analyst rating on (ELTP) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Elite Pharmaceuticals stock, see the ELTP Stock Forecast page.

Elite Pharmaceuticals to Release Q2 2026 Results Soon

Elite Pharmaceuticals announced that it will release its second quarter financial results for the fiscal year 2026 on November 14, 2025, with a conference call scheduled for November 17, 2025, to discuss these results and provide a business update. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational progress, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (ELTP) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Elite Pharmaceuticals stock, see the ELTP Stock Forecast page.